Carcinogen Identification Committee (CIC) Members

The Carcinogen Identification Committee (CIC) is a group of expert scientists appointed by the Governor to identify chemicals that have been clearly shown through scientifically valid testing according to generally accepted principles to cause cancer. (Cal. Health & Safety Code § 25249.8).

A Committee of Experts

The Carcinogen Identification Committee includes experts from among the following areas of specialization: epidemiology, oncology, pathology, medicine, public health, statistics, biology, toxicology, and related fields.

An Expert Determination

The committee meets at least once each calendar year.

The addition of a chemical to the Proposition 65 list by the committee requires three steps:

During the months prior to each meeting, scientists from the Office of Environmental Health Hazard Assessment prepare hazard identification materials, commonly in the form of a hazard identification document, presenting the scientific evidence on a chemical’s carcinogenicity. The public has an opportunity to submit relevant information to OEHHA that may be included in the materials. The hazard identification materials are released to the public for a 45-day comment period. Committee members then review the materials as well as the public comments received.
At the meetings, committee members have a chance to hear public testimony on the chemical and then review, discuss, and vote on the evidence they have seen and heard.
Members will vote on whether a chemical “has been clearly shown through scientifically valid testing according to generally accepted principles to cause cancer ….” (Cal. Health & Safety Code § 25249.8). Chemicals are added to the list of a majority of the appointed members vote “yes”.

The committee has developed guidance for its use in identifying chemicals for listing under Proposition 65 as carcinogens.

Members of the committee also have the authority to suggest and prioritize chemicals for future review. They also identify the “authoritative bodies” (such as the National Toxicology Program, the US Environmental Protection Agency, and the International Agency for Research on Cancer) whose formal identifications of carcinogens can qualify chemicals for listing by the authoritative bodies listing mechanism. (Cal. Health & Safety Code § 25249.8).

The Carcinogen Identification Committee Members Are:

Ludmil Alexandrov is a Professor in the Department of Cellular and Molecular Medicine and the Department of Bioengineering at the University of California, San Diego. Dr. Alexandrov received both his Ph.D. in Cancer Genomics and M.Phil in Computational Biology from the University of Cambridge in the UK, and his B.S. in Computer Science from Neumont University in Utah. He did his postdoctoral training at Los Alamos National Laboratory in theoretical biology and biophysics. Dr. Alexandrov has done extensive work developing knowledge on the ways factors including environmental and industrial chemicals cause cancer in humans, utilizing the latest tools in doing so. His research is focused on developing novel machine-learning approaches and in leveraging these approaches to elucidate the basic molecular mechanisms underlying cancer development and cancer progression.
Ahmad Besaratinia has been a professor of research population and public health sciences at the University of Southern California, Keck School of Medicine since 2013. His research focuses on the genetic and epigenetic mechanisms of carcinogenesis with a special emphasis on DNA damage and repair, mutagenesis, DNA methylation, and histone modifications. He received his doctorate in genetic toxicology and molecular epidemiology and his master’s degree in public health from Maastricht University in the Netherlands. He did a postdoctoral fellowship in the Department of Biology in the Beckman Research Institute of the City of Hope and held multiple positions there until 2012. He is a member of the American Association for Cancer Research, the Epigenetics Society, and the Society for Research on Nicotine and Tobacco.
Jason Bush has served as chair of the Department of Biology and professor of cancer biology at California State University, Fresno since 2019. Prior to that, he served in the same department as an associate professor from 2012 to 2019, and an assistant professor from 2006 to 2012. He was a post-doctoral fellow at the Sanford-Burnham Medical Research Institute from 2002 to 2006 and research assistant at the University of British Columbia from 1994 to 1997. He earned a Master of Science degree in zoology and a doctorate in experimental medicine from the University of British Columbia. Dr. Bush is a member of the American Association of Cancer Research, American Society for Cell Biology, American Society for Biochemistry and Molecular Biology, and US Human Proteome Organization.
Catherine Crespi has been a professor of biostatistics at the University of California, Los Angeles since 2006. Crespi earned a doctorate in biostatistics and an MS in environmental health sciences from the University of California, Los Angeles. She is a member of the University of California, Los Angeles Jonsson Comprehensive Cancer Center. Dr. Crespi has served on review panels for both the University of California Cancer Research Coordinating Committee and the National Institutes of Health, and is also a member of the editorial board for the Journal of the National Cancer Institute.
David A. Eastmond is a professor emeritus at the University of California, Riverside, having previously served as professor and chair of the Department of Cell Biology & Neuroscience until 2020. His research has centered on the metabolism and chromosome-damaging effects of various environmental chemicals. He has also participated on a variety of advisory panels related to chemical mutagenesis, carcinogenesis, and risk assessment including panels for the US Environmental Protection Agency, the US Food and Drug Administration, and the International Agency for Research on Cancer among others. He received his doctorate from the University of California, Berkeley. From 1987 to 1989, he served as an Alexander Hollaender Distinguished Postdoctoral Fellow at Lawrence Livermore National Laboratory. He recently served as the chair of the Board of Scientific Counselors for the National Toxicology Program.
Dean W. Felsher is a Professor of Medicine (Oncology) and of Pathology at Stanford University, School of Medicine. He serves as a Director of the Translational Research and Applied Medicine Center, the Medical Scientist Training Program, Advanced Residency Training Program, and one of the Principal Investigators of the Stanford Clinical and Translational Science Program. Dr. Felsher received his B.A. from the University of Chicago and his M.D. Ph.D. from UCLA. Dr. Felsher is interested in studying the causes and developing new treatments to prevent and treat cancer. Dr. Felsher along with his laboratory is studying the basic mechanisms of “Oncogene Addition”, during which cancer can be briefly reversed by shutting down oncogenes. He is developing novel therapeutics using small molecules, nanoparticles, and proteins/peptides that can be used to target oncogenes and/or restore the immune response against cancer, as well as new diagnostic and imaging methods such as PET, Mass Spectrometry and Nanoproteomics.
Joseph R. Landolph has been associate professor of molecular microbiology, immunology and pathology and associate professor of molecular pharmacology and pharmaceutical sciences at the University of Southern California since 1987. He is a member of the University of Southern California, Norris Comprehensive Cancer Center at the Keck School of Medicine. His research focuses on the molecular mechanisms of metallic compound-induced carcinogenesis. He earned a doctorate in chemistry from the University of California, Berkeley. Dr. Landolph has been a member of the Society of Toxicology since 1985.
Dana Loomis has served as Chair of the Carcinogen Identification Committee since 2024. He was Director of the Plumas County, California, Public Health Agency until his retirement in 2023, and is a former research professor at the Nevada System of Higher Education’s Desert Research Institute. From 2007 to 2010 and from 2018 to 2021, he was professor of environmental health at the University of Nevada, Reno School of Community Health Sciences. He also served as head of the International Agency for Research on Cancer’s Monographs Program in 2017, and deputy head from 2012 to 2017. From 2010 to 2012, Dr. Loomis was professor and chair of the Department of Epidemiology at the University of Nebraska Medical Center and from 1989 to 2006 he was professor of epidemiology and environmental sciences at the University of North Carolina at Chapel Hill. Dr. Loomis is a member of the International Commission for Occupational Safety and Health. He earned a doctorate in epidemiology, MPH in environmental sciences and an MS in geology from the University of North Carolina at Chapel Hill.
Mariana C. Stern is a cancer epidemiologist and has been a professor of preventive medicine and urology at the University of Southern California, Keck School of Medicine since 2001, and the Associate Director of Population Sciences for the university’s Norris Comprehensive Cancer Center. She is also the Ira Goodman Chair in Cancer Research at Keck School of Medicine. Dr. Stern was a postdoctoral fellow at the National Institute of Environmental Health Sciences from 1997 to 2001. She earned a doctorate in cancer biology from the University of Texas, MD Anderson Cancer Center and an MS in biology from the University of Buenos Aires, School of Science. She has served on panels for the evaluation of carcinogenesis and risk assessment for the International Agency for Research on Cancer.
Sophia Wang is an epidemiologist with expertise in molecular epidemiology and cancer etiology and has been a professor at City of Hope National Medical Center since 2009. Prior to joining the City of Hope, Dr. Wang was an intramural investigator at the National Cancer Institute. Her research focuses on evaluating the role of environmental and genetic risk factors for developing lymphomas and other types of cancer, as well as investigating cancer risks in populations living in California. Dr. Wang completed her post-doctoral fellowship at the Centers for Disease Control and Prevention, where she served as an Epidemic Intelligence Service Officer. She received her undergraduate training at the Massachusetts Institute of Technology and obtained her doctorate from the Johns Hopkins Bloomberg School of Public Health. She serves as a Steering Committee member to the California Teachers Study cohort, where she evaluates the causes of multiple cancers. She is also an active researcher in large international consortia, including the International Lymphoma Epidemiology (InterLymph) Consortium, for which she served as chair in 2013, and the National Institutes of Health’s Cancer Genome Atlas Cervix Working Group.